Jump to navigation

Home
  • About Biostage
    • Mission and Values
    • Leadership
    • Board of Directors
    • Scientific Advisory
    • Pipeline
    • Partnering
  • Therapeutic Needs
    • Esophageal Atresia
  • Cellspan Implants
    • Cellspan Esophageal Implants
    • Cellspan Bronchial Implants
    • Cellspan Tracheal Implants
    • Study Updates
  • Cellframe Technology
  • Investors
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financial Filings
    • Investor FAQs
    • Stock Information
  • Media
    • In the News
  • Careers
  • Twitter icon
  • LinkedIn icon

Biostage Submits Investigational New Drug (IND) Application for Lead Product Candidate Cellspan™ Esophageal Implant for Treatment of Esophageal Conditions

Biostage's technology has the potential to not only avoid multiple complex surgeries, but also improve the patient's quality of life compared to the current standard of care. >>>

  • Biostage Reports Third Quarter 2020 Financial Results
  • Biostage Announces IND Approval from FDA for its Lead Product Candidate Cellspan™ Esophageal Implant
  • Clinical Study Updates
  • Latest Corporate Presentation
  • Cellframe Technology Recognized by National Instruments
  • Learn More About Esophageal Atresia
  • Biostage in the News
  • Cellframe Technology in Action

Esophageal Atresia:
A Life-Threatening Condition
that Demands Effective Treatment

Approximately 1 in 4,000 babies, in the US alone, are born with this congenital defect. Find out how Biostage is working to answer this unmet medical need. >>>

Cellspan™ Implants:
Signal and Guide Regeneration

Bioengineered implants guide the regeneration of a biological structure. Learn how stem cells adhere to and interact with the implant. >>>

  • Privacy Policy
  • Terms of Use
  • Search
  • Contact

©2021 Biostage. All rights reserved.